OBJECTIVE: Current anti-obesity monotherapies have proven only marginally effective and are often accompanied by adverse side effects. The cannabinoid 1 (CB1) receptor antagonist rimonabant, while effective at producing weight loss, has been discontinued from clinical use owing to increased incidence of depression. This study investigates the interaction between the cannabinoid and melanin-concentrating hormone (MCH) systems in food intake, body weight control, and mood. DESIGN: Lean male C57BL/6 mice were injected i. ) to establish dose response parameters for each drug. Diet-induced obese (DIO) mice were given either vehicle, sub-threshold dose of rimonabant and SNAP-94847 alone or in combination. Impact on behavioral outcomes, food intake, body weight, plasma metabolites and expression of key metabolic proteins in the brown adipose tissue (BAT) and white adipose tissue (WAT) were measured. RESULTS: The high doses of rimonabant and SNAP-94847 produced a reduction in food intake after 2 and 24 h. Combining sub-threshold doses of rimonabant and SNAP-94847 produced a significantly greater loss of body weight in DIO mice compared with vehicle and monotherapies. In addition, combining sub effective doses of these drugs led to a shift in markers of thermogenesis in BAT and lipid metabolism in WAT consistent with increased energy expenditure and lipolysis. Furthermore, co-administration of rimonabant and SNAP-94847 produced a transient reduction in food intake, and significantly reduced fat mass and adipocyte size. Importantly, SNAP-94847 significantly attenuated the ability of rimonabant to reduced immobility time in the forced swim test. CONCLUSION: These results provide proof of principle that combination of rimonabant and a MCH1 receptor antagonist is highly effective in reducing body weight below that achieved by rimonabant and SNAP-94847 monotherapies. In addition, the combination therapy normalizes the rimonabant-induced behavioral changes seen in the forced swim test.
INTRODUCTION
Obesity is a global 'epidemic' with B500 million adults worldwide considered to be either overweight or obese (World Health Organization, Fact Sheet No. 311, March 2011). This epidemic has proven resistant to pharmacological treatment because of limited efficacy and associated adverse side effects. 1 This highlights the critical need to develop new treatments that are safe, effective and with few adverse effects.
Compounds that reduce endogenous cannabinoid 1 (CB1) receptor activity such as rimonabant 2 had taken center stage as a frontline anti-obesity therapeutic. 3 --6 Specifically, in phase III clinical trials (RIO Europe) rimonabant was shown to produce, after 1 year of treatment, 5% weight loss in 67% of individuals and 10% or more weight loss in 39% of participants. Importantly, in these individuals there was a significant targeting of weight loss of the abdominal fat, demonstrating the ability to rimonabant to combat the spectrum of pathologies associated with the metabolic syndrome. 3, 4, 6 Despite this proven efficacy, rimonabant was discontinued as an anti-obesity pharmacotherapy on the basis of adverse psychiatric outcomes. 4 However, it would be premature to abandon rimonabant as a frontline anti-obesity therapeutic. A number of potential approaches could be explored to circumvent rimonabant's negative impact on mood while retaining or even enhancing its weight loss inducing effects. One possible avenue is to administer rimonabant in combination with antagonists of hypothalamic peptidergic systems that in addition to suppressing appetite also produce a positive impact on mood.
Antagonists to the melanin-concentrating hormone (MCH) are prime candidates for such combination therapies. For example, antagonizing the MCH1 receptor with SNAP-7941 reduces obesity despite a transient reduction in food intake 7 suggesting an impact on energy expenditure. Indeed, sub-chronic intracerebroventicular infusing of SNAP-7941 elevates brown adipose tissue (BAT) temperature in conjunction with an increase in the expression of uncoupling protein (UCP) 1. 8 Furthermore, mice lacking the MCH1 receptor display a hypophagic and lean phenotype. 9 With regard to mood related effects, MCH1 receptor deletion or blockade results in anti-depressant like properties in the forced swim test. 7, 10 These studies clearly demonstrate the impact of antagonizing MCH1 receptors on food intake, body weight and mood regulation.
The case for combining rimonabant with an MCH1 receptor antagonist is made stronger by the demonstrated interactions between these systems. For example, CB1 receptor mRNA is localized on MCH producing neurons in the lateral hypothalamus. 11 The activity of the MCH neurons is stimulated by acute CB1 receptor activation. 12 Furthermore, chronic attenuation of the CB1 receptor by rimonabant produces an increase in the expression of MCH protein and mRNA in the hypothalamus. 13 Extrapolating from these studies, it is feasible that rimonabant-induced negative mood could be alleviated by blocking the MCH1 receptors. Therefore, this study was designed to assess whether rimonabant's well-known negative impact on mood could be attenuated by combined treatment with another MCH1 receptor antagonist SNAP-94847. In addition to mood, impact on food intake, body weight, plasma metabolites and expression of key metabolic genes in the BAT and white adipose tissue (WAT) were also measured.
MATERIALS AND METHODS

Animals and drugs
Experimentally naïve male C57BL/6 mice were housed in opaque polypropylene cages with stainless steel wire lids. Cages were lined with dust-free wood chips and were housed in a climate-controlled (20 --23 1C) room maintained on a 12-h reverse light, 12-h dark cycle (lights off at 0010 hours). All animals were treated in accordance with the 'Principles of Laboratory Animal Care' (NIH publication No. 85 --23, revised 1985) and the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. This study was reviewed and approved by the Monash University School of Biomedical Science Animal Ethics Committee.
Research Products (Pangbourne, UK)) was mixed as previously described. 14 The MCH receptor antagonist SNAP-94847 (Tocris Biosciences, Bristol, UK) was dissolved in 20% (w/v) encapsin (hydroxypropyl beta-cyclodrextrin; ICN Biomedicals, Irvine, CA, USA) in distilled water. Both drugs and their vehicle were injected at the start of the dark cycle.
Dose-dependent effect of Rimonabant and SNAP-94847 on food intake
In order to determine the sub-anorectic doses of rimonabant and SNAP-94847, C57BL/6J mice (Animal Resource Centre, Perth; N ¼ 8) 8 weeks of age were maintained on laboratory chow diet (GR2 rat and mouse cubes; Ridley AgriProducts, Pakenham, Victoria, Australia). Bottles filled with tap water were available at all times. Before the start of drug treatment mice were food deprive for 12 h in order to obtain a higher baseline of food intake in vehicle treated animals. Next, mice were injected at the start of the dark cycle with either vehicle or rimonabant (0.03, 0.3 or 3.0 mg kg
À1
) and given a pre-weighed amount of food. The total amount of food consumed was determined 2 and 24 h post injection. After a 2-week washout, the same animals were again food deprived for 12 h and injected with either vehicle or SNAP-94847 (1.0, 5.0 or 10.0 mg kg
) and food intake measured as described above. The two drugs or their vehicles were injected every 48 h in order to allow sufficient washout time between doses. All mice received all treatments in a counter-balanced order. On the day between drug sessions, animals were injected with vehicle and treated as per the experimental protocol and total food consumed measured. Food intake was measured during this time in order to ascertain drug wash out.
Combined effect of Rimonabant and SNAP-94847 on food intake, body weight and energy efficiency in diet-induced obese (DIO) mice
Once the sub-anorectic dose of rimonabant and SNAP-94847 was determined, C57BL/6J mice 6 weeks of age (Animal Resource Centre, Perth; N ¼ 24) were maintained on a high-fat diet (HFD) ( 
Blood chemistry
At the end of the 21-day treatment period, animals were food deprived for 6 h and put under deep fluothane anesthesia and blood samples taken via cardiac puncture and collected in 1 ml EDTA tubes (Greiner Bio-One GmbH, Frickenhausen, Germany). Blood samples were then centrifuged at 4000 g for 5 min at 4 1C. Plasma total nonesterified fatty acids (NEFA; Wako Diagnostics, Richmond, VA, USA), triglycerides (TG) (Roche Diagnostics, Indianapolis, IN, USA), insulin (Crystal Chem Inc., Downers Grove, IL, USA) and aspartate transaminase ((AST), BioAssay Systems, Hayward, CA, USA) were measured according the manufactures protocol. Plasma glucose and lactate concentrations were measured in 25-ml samples using a YSI2300 STAT glucose/L-lactate analyzer (YSI, Inc., Yellow Springs, OH, USA).
In addition, we also measured the impact of acute treatment with Veh/ Veh, Rim/Veh, Veh/SNAP and Rim/SNAP treatment on glucose metabolism using a glucose tolerance test (GTT) and insulin tolerance test (ITT). All drugs and vehicle were injected at a volume of 5 ml kg À1 . Drug and vehicle were given 1 h before commencement of glucose and ITTs. Each mouse received 1 g kg À1 glucose in a 25% w/v solution in saline or 1 U kg À1 insulin injected in a volume of 5 ml kg
À1
. Blood glucose was measured using a handheld glucometer (Accu-chek, Roche) before glucose and insulin administration and at 15, 30, 60 and 120 min post administration.
Markers of thermogenesis and lipid metabolism
Following blood collection animals were decapitated and BAT, inguinal WAT (iWAT) and retroperitoneal WAT (rWAT) were removed. The white fat pads represented subcutaneous and abdominal depots, respectively. The BAT, rWAT and iWAT were first weighed and a small sample was snap frozen and stored at À80 1C for further analysis.
Protein from the BAT and rWAT was extracted as previously described. Following secondary antibody incubation using anti-rabbit HRP (1:4000 for ATGL, AMPK and pAMPK T172) and anti-goat HRP (1:4000 for UCP1) protein expression signals were visualized by chemiluminescence using the Pierce ECL western blotting substrate (Thermo Scientific, Rockford, IL, USA) on Kodak Biomax X-ray film (Kodak, Rochester, NY, USA). Relative densities of protein bands were assessed using Image J software (National Institutes of Health, Bethesda, MD, USA).
Adipocyte area
Following extraction of rWAT and iWAT, a small piece of each of the white fat depots were immersed in Bouin's solution overnight and then transferred to 70% ethanol and stored at 4 1C. Tissues were fixed and embedded with a random orientation in paraffin and 10-mm sections were stained with hematoxylin and counterstained with eosin. For each sample, the adipocyte cell size was determined qualitatively at Â 400 magnification using a Zeiss Imager Z1 microscope (Carl Zeiss, North Ryde, New South Wales, Australia , a relatively high dose known to cause a significant reduction in immobility time. SNAP-94847 was given at a dose of 5 mg kg À1 .
Statistical analysis
Daily food intake (g) and body weight were used as dependent variables and analyzed separately. Specifically, total food intake and body weight for each day for each group was averaged and analyzed using a repeated measures (treatment by day) analysis of variance with day as the repeated factor. Where significant main effects were found, pairwise comparisons were conducted using Bonferroni adjustments for multiple comparisons. Mauchly's W was computed to check for violations of the sphericity assumptions. When Mauchly's W-test was significant, the Greenhouse --Geisser correction was applied. For the rimonabant and SNAP-94847 dose response, western blot, iWAT, rWAT, BAT, and plasma NEFA, TGs, insulin, AST, glucose and lactate levels were analyzed using a one-way analysis of variance to determine if the total food consumed; protein expression, fat pad weights and NEFA, TGs, insulin, AST, glucose, lactate, GTT and ITT levels of the various groups were significantly differentially affected by the treatment. Porsolt's forced swim test results were analyzed with either a one-way analysis of variance with a Tukey's post hoc test or t-test as appropriate.
RESULTS
Dose effect of Rimonabant and SNAP-94847 on food intake
The mean quantity of food consumed before rimonabant and SNAP-94847 treatment did not differ significantly between the treatment groups. As a result there was no significant difference in the mean body weights of each treatment group at the start of the experiment. In order to determine the sub-anorectic dose of rimonabant and SNAP-94847, animals were administered a single dose of vehicle, 0.03, 0.3 or 3.0 mg kg À1 rimonabant and either vehicle, 1.0, 5.0 or 10.0 mg kg À1 SNAP-94847 just before the start of the dark phase and food consumed at the 2 and 24 h was measured. Total food consumed at the 2-h measurement interval was depressed following administration of the 0.3 and 3.0 mg kg À1 dose of rimonabant. However, the reduction in food intake reached significance only at the 3.0 mg kg À1 dose of rimonabant (F(3, 28) ¼ 66.20, Po0.001) (Figure 1a) . Similarly, the 24-h food intake was also significantly reduced following injection of 3.0 mg kg À1 rimonabant (F(3, 28) ¼ 16.19, Po0.001) (Figure 1b ). Similar to rimonabant, the 5.0 and 10.0 mg kg À1 dose of SNAP-94847 reduced 2-h food intake that reached significance only at the highest dose tested (10.0 mg kg À1 ) (F(3, 28) ¼ 144.00, Po0.001) (Figure 1c ). This reduction in food intake was also evident 24 h post injection (F(3, 28) ¼ 37.80, Po0.001) (Figure 1d ). It is important to note that the 48 h allowed between the treatments was sufficient to produce a complete drug washout as the food consumed did differ between the groups (data not shown). (Figure 3a) . Interestingly, the food intake was significantly depressed for the first 8 days out of the 21-day treatment period (F(36, 240) ¼ 6.62, Po0.001) (Figure 2a) , while the rate of body weight loss was constant despite a transient reduction in food intake (F(3, 20) ¼ 16.32, Po0.001) (Figure 2b) . It is essential to note that body weight loss following the combined administration of Rim/SNAP did not appear to plateau when treatment was terminated on day 21 (Treatment by time interaction (F(36, 240) ¼ 14.05, Po0.01)) (Figure 2b) . Next, we calculated feed efficiency (weight gain per kilocalorie ingested) for the entire 21-day treatment period (Figure 2c (Figure 4c ) fat mass was significantly lower in the animals injected with Rim/SNAP compared with vehicle and monotherapies. Rim/Veh and Veh/ SNAP did not significantly reduce fat mass in any of the fat depots measured. Importantly, following combined treatment the fat mass of the BAT was reduced by 50%, rWAT by 65% and iWAT by 40% compared with veh/veh, Rim/Veh and Veh/SNAP.
The reduced rWAT and iWAT weights were commensurate with changes with adipocyte cell size. Specifically, the mice receiving the combined treatment showed a qualitatively reduced adipocyte cell size when compared with Veh/Veh, Rim/Veh and Veh/ SNAP. A representative image of the rWAT and iWAT is shown in Figure 4 . Effect on Porsolt's forced swim test To investigate the impact of SNAP-94847 on rimonabant-induced changes in mood, drugs were administered alone or in combination followed by a Porsolt's forced swim test. The same daily doses of rimonabant and SNAP-94847 that resulted in reductions in food intake and body weight when combined (Figure 2 ) produced no alterations in immobility time in this test (Figure 6a ). The 0.3 mg kg À1 dose of rimonabant used in all feeding and metabolic experiments in this paper did not alter mobility in the test when administered in isolation, indicating that this dose is actually subthreshold for inducing behavioral change in mice (Figure 6b) . We additionally tested a dose of 10 mg kg À1 rimonabant, previously shown to produce a robust reduction in immobility time, which was recapitulated here with a significant decrease compared with veh/veh and the individual drug treatments (F(2, 39) ¼ 13.68; Po0.05). Most interestingly, when we combined the effective 10 mg kg À1 dose of rimonabant with a sub-anorectic dose of SNAP-94847 (5.0 mg kg À1 ) we saw a normalization of the rimonabant-induced reduction in immobility time, resulting in data indistinguishable from Veh/Veh-treated mice.
DISCUSSION
The current data provide compelling evidence for a functional interaction between CB1 and MCH1 receptor antagonism in body weight regulation in the face of only a transient reduction in food intake. The positive impact on weight loss in response to rimonabant and SNAP poly-treatment induced a reduction in the fat mass of the BAT, rWAT and iWAT that is commensurate with a change in adipocyte cell size seen in the iWAT and rWAT. This reduction in body weight was associated with increased expression of fasting-induced plasma NEFA and reduction in fasting-induced insulin, TG, AST, glucose and lactate. Furthermore, the expression of genes associated with, thermogenesis in BAT and lipid metabolism in the WAT shifted in the directions consistent with increased energy expenditure and lipolysis. Most importantly, we demonstrate for the first time that blocking MCH1 receptor signaling attenuates rimonabant's effect in the Porsolt's forced swim test, a screening test for antidepressant drugs. These findings indicate that the MCH1 receptor has an important role in psychological side effects of rimonabant and suggests the exciting opportunity for the development of sophisticated combination therapy specifically targeting the CB1 and MCH1 receptor systems.
The present findings with regard to a dose-dependent reduction in feeding following the acute administration of rimonabant are consistent with previous studies, 16 --19 and further support the role of the cannabinoid system in mediating energy balance (for a review see Bermudez-Silva et al. 20 ). Similarly, the dose-dependent reduction in food intake in response to SNAP-94847 complements previous studies showing similar effects with another MCH1 receptor antagonist SNAP-7941, 7, 8 and further demonstrates the role of the MCH1 receptor in energy homeostasis (for a review see Pissios 21 ). The data presented here show for the first time that the combined administration of sub-anorectic doses of rimonabant and SNAP-94847 produces a profound and sustained reduction in body weight in the face of a transient reduction in food intake using a nongenetic model of obesity. These findings strongly implicate energy expenditure as a mechanism underlying the antiobesity effect of the Rim/SNAP combination. This suggestion is borne out by the findings that Rim/SNAP induces shifts in markers of thermogenesis (UCP1) and lipolysis (ATGL). These changes are consistent with an increase in catabolic process in the WAT and BAT that collectively enhance weight loss. 22, 23 With regard to BAT thermogenic activity, this finding is in agreement with our recent studies showing an elevation of BAT temperature and UCP1 expression following chronic and sub-chronic dosing with rimonabant 14, 24 and SNAP-7941, 8 respectively. Our results suggest that when given in combination, rimonabant and SNAP-94847 produce a profound elevation in BAT thermogenesis resulting in a marked increase in UCP1 expression.
Some insight into the site and nature of the brain mechanisms underpinning the interaction of CB1 and MCH1 receptors comes from electrophysiological data 12, 25 showing that CB1 agonists acting at presynaptic sites on afferents to MCH neurons in the lateral hypothalamus cause a depolarization-induced suppression of inhibition leading ultimately to an increased release of MCH. Although not tested directly in these papers, the corollary of the observation described above is that antagonism of the receptor should reduce the MCH released, potentially diminishing the efficacy of the MCH receptor antagonist in our co-administration experiments. It is difficult, however, to reconcile directly the effects of mM amounts of CB1 agonists delivered to neurons in hypothalamic slices, 12 with the sub-anorectic doses of rimonabant shown in our experiments to synergise with MCH1-R antagonists to reduce food intake and body weight.
In order to determine the mechanism by which the combination of both drugs impacts on catabolic processes in the various fat depots we examined the role of AMPK. Our data show that the changes in lipolysis could be mediated via cannabinoid and MCH actions on AMPK. It is well established that AMPK activation inhibits lipogenesis and stimulates lipid oxidation. 26 Rimonabant has been shown to activate the expression of AMPK in the WAT, 27 whereas MCH mRNA is inhibited by activation of AMPK. 28 Hence, the combined administration of rimonabant and SNAP-94847 could activate AMPK that in turn inhibits deposition of fat and enhance the breakdown and burning of fat stores resulting in reduced body weight.
Hyperinsulinemia, hypertriglyceridemia and insulin resistance are commonly linked with human obesity. 29 A similar profile was evident in the DIO mice used in the current study. In this model, Rim/SNAP treatment reduced plasma insulin levels and TG levels. Given that plasma insulin and TG levels are negatively correlated with the degree of adiposity, 30, 31 the Rim/SNAP-induced weight loss may contribute to improvements in these plasma parameters. A direct effect of treatment remains a possibility, however, our data showing a lack of effect of Rim/SNAP in the GTT and ITT would suggest that this is not the case. In our model, NEFA levels were significantly increased in DIO mice treated with Rim/SNAP compared with Veh/Veh, Rim/Veh and Veh/SNAP. These findings are consistent with studies showing an increase in plasma NEFA concentration following their release from adipose tissue as a result of enhanced lipolysis. 32, 33 This finding is consistent with the current data showing a significant increase in markers of lipolysis in the WAT after Rim/SNAP treatment. In addition to insulin, TG and NEFA, Rim/SNAP significantly reduced AST blood levels. AST is a metabolic enzyme expressed primarily in the liver whose elevation is one of the hallmarks of the whole spectrum of nonalcoholic fatty liver disease that occurs with increasing obesity. 34 The reduction in AST levels seen following Rim/SNAP, clearly indicates an improvement in liver function and a reduction in obesity-induced nonalcoholic fatty liver disease. The roles of MCH1 and CB1 receptor signalling in mood are complicated, however, the evidence points towards them having opposing actions. As previously mentioned, rimonabant has been shown to promote depression in human studies, 35, 36 whereas MCH1 receptor antagonism produces an anti-depressant profile in rodent behavioral tests. 7, 10 Given that CB1 and MCH1 receptors are localized within the striatal regions regulating mood 37, 38 and the demonstrated interaction between CB1 and MCH1 receptors 8, 11, 12 we hypothesized that MCH1 receptor signaling may be responsible for rimonabant's negative impact on mood. The current data showing a noneffective dose of SNAP completely ameliorating rimonabant's effect on immobility support this notion.
A reduction in immobility time in the Porsolt's forced swim test is generally interpreted as an anti-depressive effect, a conclusion drawn from the ability of a number of anti-depressant drugs to reduce immobility during the test. The current data show a decrease in immobility time following high dose rimonabant treatment, which is at odds with the observed pro-depressive effects in the human population. The forced swim test has reasonable predictive validity for antidepressant drugs, however, it is not a model of human depression per se. Indeed, it has been suggested that 'the forced swim test does not induce depression (and therefore is not a model of depression-like behavior), but can detect antidepressant effects (as a test)'. 39 The reduction in immobility following rimonabant treatment is consistent with previous reports using this drug in mice, 40, 41 and the value of the results presented here stem from the ability of the SNAP compound to completely block a stereotypical behavior induced by rimonabant. The fact that the polarity of the change is opposite to the hypothetically 'correct' direction is of less consequence than amelioration of the effect itself by the MCH1 receptor antagonist. This finding suggests that MCH1 receptors mediate behavioral changes caused by rimonabant and further suggests that the mood-altering effect of rimonabant can be significantly attenuated.
In summary, CB1 receptor antagonists have demonstrated efficacy in stimulating weight loss in obese individuals and confer additional metabolic benefits. However, CB1 receptor antagonists have been withdrawn from clinical use primarily because of concerns about their side effects on mood particularly increased depression. The present result using DIO mice clearly provide proof of principle that the combination of rimonabant and an MCH1 receptor antagonist is efficacious in reducing body weight below that achieved by rimonabant and SNAP monotherapies after normalizing mood-related behavior. These data suggest a novel and attractive opportunity to develop pharmacotherapy targeting both the CB1 and MCH1 receptor systems.
